View Older Stories View More Recent Stories
-
EyePoint Inc. (EYPT) PT Lowered to $48 at Laidlaw
-
Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
-
JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral
-
EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
-
Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'
-
Cantor Fitzgerald Downgrades EyePoint Inc. (EYPT) to Neutral
-
Citi cuts EyePoint price target to $17 from $35, keeps Buy, stock down 67%
-
EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 15c
-
Citi opens 90-day upside catalyst call on EyePoint
-
EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick'
-
EyePoint Pharmaceuticals settles False Claims Act case for $4.7M
-
Stifel Starts EyePoint Inc. (EYPT) at Buy
-
Cantor Fitzgerald Assumes EyePoint Inc. (EYPT) at Overweight
-
These 5 stocks are added to The Mizuho Top Picks List for July
-
Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT)
-
Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
-
Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT)
-
EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Guggenheim Reiterates EyePoint (EYPT) at Buy, "EYPT remains one of our Top Picks"
-
Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT): "view recent weakness as a buying opportunity"
-
EyePoint Inc. (EYPT) PT Raised to $35 at Citi
-
EyePoint Inc. (EYPT) PT Raised to $30 at H.C. Wainwright
-
EyePoint Inc. (EYPT) PT Raised to $29 at Chardan
-
EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 6c
-
Guggenheim Reiterates EyePoint at (EYPT) at Buy, 'remains one of our Top Picks'
-
RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity'
-
Mizuho on EyePoint Inc. (EYPT): 'Competitor P3 Data Coming, So Expect Volatility; Recent Weakness Provides an Opportunity'
-
Mizuho: 'we again highlight EYPT as a top pick for 2026'
-
RBC Capital on EyePoint Inc. (EYPT): 'we see weighted avg. upside of ~60% into EYPT's wAMD Phase III readout'
-
EyePoint advances retinal drug trials with 2026 data readouts expected
-
Here are Mizuho's top Biotech pick for 2026
-
Here's the list of top biotech stocks to own for 2026
-
Mizuho on EyePoint Inc. (EYPT): 'Competitor Makes a Move for the Pole Position; Reiterate OP, as We're Not Concerned'
-
EyePoint Pharmaceuticals (EYPT) Changes Names to Eyepoint Inc - SEC
-
H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c
-
Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
EyePoint Pharmaceuticals (EYPT) files mixed shelf
-
Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $28 at Mizuho
-
EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c
-
H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
JPMorgan on EyePoint Pharmaceuticals, Inc. (EYPT): 'We are pleased to see EyePoint’s continued execution'
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $26 at Mizuho
-
EyePoint Pharmaceuticals (EYPT) Tops Q1 EPS by 2c
-
Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
These 11 stocks are Mizuho's Aging Intelligence (AI) top picks
-
H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 14c

